OPU
TRIL

Omni Partners US’s Trillium Therapeutics Inc. TRIL Stock Holding History

Omni Partners US’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$41.6M Buy
+2,366,824
New +$27.7M 2.13% 10

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Omni Partners US's TRIL Position: Q3 2021 in Review

Omni Partners US opened a new position in Trillium Therapeutics Inc. (TRIL) in Q3 2021: 2,366,824 shares worth $41.6M. The stake represents 2.13% of the portfolio and ranks #10 among its holdings.

181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Omni Partners US held 2,366,824 shares of Trillium Therapeutics Inc. worth $41.6M as of Q3 2021.
  • Trillium Therapeutics Inc. was a new Omni Partners US position in Q3 2021.
  • Trillium Therapeutics Inc. made up 2.13% of Omni Partners US's portfolio in Q3 2021, its #10 holding.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.